Inflamax introduces ePDAT for real-time PRO data collection

Article

New tablet facilitates and standardizes patient reported outcomes data collection.

Toronto, Ontario-Inflamax Research has introduced its electronic Patient Data Acquisition Tablet (ePDAT) which not only facilitates but standardizes patient reported outcomes (PRO) data collection across multi-center clinical trials.

The validated ePDAT system provides a graphical user interface via a touchscreen tablet computer designed to provide an improved user experience. The system was designed to enhance user experience, accuracy, and quality while ensuring compliance with FDA and EMA requirements for validated ePRO data collection tools. ePDAT is fully CFR21 part 11 compliant.

PRO data can be collected by on-screen questionnaires, visual analog scales (VAS), response time, coordination tasks, high-resolution image capture, and evaluator interview via video conferencing.

Software architecture allows patient data to be recorded in real-time via the tablet’s cellular wireless connection to the company’s secure database servers. Data is also stored locally on the tablet as backup. 

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.